Observational studies and meta-analyses pooling GLP-1 RA trials largely suggest no overall increased risk of diabetic retinopathy, supporting the interpretation that the SUSTAIN-6 signal reflects context-specific rather than drug-class harm. This evidence concerns the gene GLP1R and diabetic retinopathy.